Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893746 | 0.92 | TRPA1 (0.39) | L3MBTL1TRPA1 | |
| SCHEMBL10164586 | 0.89 | LMNA (0.41) | MAPTLMNAMEN1KMT2ATRPA1 | |
| SCHEMBL10164507 | 0.88 | L3MBTL1 (0.47) | THRBMAPTLMNAMEN1KMT2A | |
| SCHEMBL10164512 | 0.88 | LMNA (0.44) | THRBMAPTLMNAMEN1KMT2A | |
| SCHEMBL10164625 | 0.87 | ALDH1A1 (0.36) | MAPTLMNAMEN1KMT2ATP53 | |
| SCHEMBL10164521 | 0.86 | ALDH1A1 (0.38) | MAPTLMNATRPA1POLBNPSR1 | |
| SCHEMBL10164563 | 0.86 | THRB (0.38) | THRBMAPTLMNAMEN1KMT2A | |
| SCHEMBL10164609 | 0.82 | TRPA1 (0.38) | MAPTLMNAMEN1KMT2ATP53 | |
| SCHEMBL10164705 | 0.82 | MAPT (0.37) | MAPTLMNAMEN1KMT2ATP53 | |
| SCHEMBL893849 | 0.82 | LMNA (0.40) | LMNATRPA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | THRB 2126/4885MAPT 1004/4885LMNA 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.